𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors in patients with non-small cell bronchogenic carcinoma and brain metastases

✍ Scribed by E. Robin; J. D. Bitran; H. M. Golomb; S. Newman; P. C. Hoffman; R. K. Desser; T. R. Demeester


Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
343 KB
Volume
49
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Prognostic factors for survival in patie
✍ StΓ©phane Culine; Mohamed Bekradda; Andrew Kramar; Annie Rey; Bernard Escudier; J πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 2 views

The authors thank S. Ne Β΄grier, M.D., A. Ravaud, M.D., and G. Chvetzoff for providing the clinical charts of patients included in the external data set.

Benefits of polychemotherapy in advanced
✍ Yvon Cormier; Dollard Bergeron; Jacques La Forge; Michel Lavandier; Marcien Four πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 377 KB πŸ‘ 1 views

The benefits of polychemotherapy in advanced (Stage 111) non-small-cell bronchogenic carcinoma remain uncertain. In attempt to answer the important question whether treatment improves well-being and survival in these patients, we did a prospective, randomized, single-blind study to compare polychemo

Intracranial metastases in small cell ca
✍ Fred R. Hirsch; Olaf B. Paulson; Heine H. Hansen; S. Olesen Larsen πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 432 KB πŸ‘ 2 views

Two hundred-twelve consecutive patients with small cell carcinoma of the lung were studied in order to correlate the risk of developing intracranial metastases to the initial stage of the disease (locoregional versus extensive) and to evaluate the prognostic significance of developing intracranial d

Prognostic factors in patients with recu
✍ Asakawa, Hideki; Kobayashi, Tetsuro; Komoike, Yoshifumi; Tamaki, Yasuhiro; Matsu πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 100 KB πŸ‘ 1 views

Background: Approximately 20% of patients with thyroid carcinoma have relapse. To evaluate the factors affecting their disease-free survival and prognosis, we studied 68 patients with recurrent differentiated thyroid carcinoma, ranging in age from 5 to 73 years (mean: 47.6 years). Threefourths of pa